3,3'-Diindolylmethane suppresses the growth of gastric cancer cells via activation of the Hippo signaling pathway

Li,Xiu Juan; Park,Eun Sung; Park,Man Hee; Kim,Soo  Mi

doi:10.3892/or.2013.2717

3,3'-Diindolylmethane suppresses the growth of gastric cancer cells via activation of the Hippo signaling pathway

Authors:
- Xiu Juan Li
- Eun Sung Park
- Man Hee Park
- Soo Mi Kim
View Affiliations

Affiliations: Department of Physiology, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju, Republic of Korea, Institute for Medical Convergence, Yonsei University College of Medicine, Seoul, Republic of Korea, Catholic University of Pusan, Busan, Republic of Korea
Published online on: September 4, 2013 https://doi.org/10.3892/or.2013.2717
Pages: 2419-2426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have revealed that 3,3-diindolylmethane (DIM) has antitumor effects in both in vivo and in vitro tumor models. However, the biological function of DIM in human gastric cancer cells is unknown. Genetic and biological studies have confirmed the importance of the novel Hippo tumor-suppressor pathway in regulating cell proliferation, apoptosis, organ size and tumorigenesis in mammals. Thus, the purpose of this study was to investigate the cytotoxic effects of DIM in human gastric cancer cells and to elucidate whether DIM induces cell death by activating the Hippo signaling pathway. Two human gastric cancer cell lines (SNU-1 and SNU-484) were used to investigate the DIM response. DIM significantly inhibited the proliferation of human gastric cancer cells in a dose-dependent manner. The percentage of G1 phase cells increased 24 h following DIM treatment. DIM reduced CDK2, CDK4, CDK6 and cyclin D1 protein levels, while increasing p53 protein levels. DIM induced the levels of cleaved poly(ADP-ribose) polymerase, cleaved-caspase-9, and diminished pro-caspase-3 protein production. In addition, DIM increased pLATS1, Mob1, pMob1, pYAP and Ras association domain family 1 (RASSF1) protein levels and reduced Yap protein production levels. DIM stimulated the binding of RASSF1 with the Mst1/2-LATS1-Mob1 complex, promoting an active Hippo signaling pathway and favoring YAP phosphorylation (pYAP) that inactivates cell proliferation. Furthermore, DIM inhibited the growth of human gastric tumors in a xenograft mouse model. These results indicate that DIM suppresses the growth of gastric cancer cells by activating the Hippo signaling pathway.

View Figures

View References

1	Kong D, Banerjee S, Huang W, et al: Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res. 68:1927–1934. 2008.
2	Shin HR, Carlos MC and Varghese C: Cancer control in the Asia Pacific region: current status and concerns. Jpn J Clin Oncol. 42:867–881. 2012. View Article : Google Scholar : PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
4	Tan IB, Ng I, Tai WM and Tan P: Understanding the genetic basis of gastric cancer: recent advances. Expert Rev Gastroenterol Hepatol. 6:335–341. 2012. View Article : Google Scholar : PubMed/NCBI
5	Hoffmann W: Stem cells, self-renewal and cancer of the gastric epithelium. Curr Med Chem. 19:5975–5983. 2012. View Article : Google Scholar : PubMed/NCBI
6	Cho JY, Lim JY, Cheong JH, et al: Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 17:1850–1857. 2011. View Article : Google Scholar : PubMed/NCBI
7	Hundahl SA, Phillips JL and Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the ‘different disease’ hypothesis. Cancer. 88:921–932. 2000.PubMed/NCBI
8	Kovoor PA and Hwang J: Treatment of resectable gastric cancer: current standards of care. Exp Rev Anticancer Ther. 9:135–142. 2009. View Article : Google Scholar : PubMed/NCBI
9	Rausei S, Dionigi G, Rovera F, et al: A decade in gastric cancer curative surgery: evidence of progress (1999–2009). World J Gastrointest Surg. 4:45–54. 2012.PubMed/NCBI
10	Harvey KF, Pfleger CM and Hariharan IK: The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 114:457–467. 2003.
11	Harvey K and Tapon N: The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 7:182–191. 2007. View Article : Google Scholar : PubMed/NCBI
12	Grusche FA, Richardson HE and Harvey KF: Upstream regulation of the hippo size control pathway. Curr Biol. 20:R574–R582. 2010. View Article : Google Scholar : PubMed/NCBI
13	Harvey KF and Hariharan IK: The hippo pathway. Cold Spring Harb Perspect Biol. 4:a0112882012. View Article : Google Scholar : PubMed/NCBI
14	Zeng Q and Hong W: The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell. 13:188–192. 2008. View Article : Google Scholar : PubMed/NCBI
15	Edgar BA: From cell structure to transcription: Hippo forges a new path. Cell. 124:267–273. 2006. View Article : Google Scholar : PubMed/NCBI
16	Zhao B, Li L, Lei Q and Guan KL: The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
17	Xu ZP, Zhu JS, Zhang Q and Wang XY: A breakdown of the Hippo pathway in gastric cancer. Hepatogastroenterology. 58:1611–1617. 2011.PubMed/NCBI
18	Zhou Z, Zhu JS, Xu ZP and Zhang Q: Lentiviral vector-mediated siRNA knockdown of the YAP gene inhibits growth and induces apoptosis in the SGC7901 gastriccancer cell line. Mol Med Rep. 4:1075–1082. 2011.PubMed/NCBI
19	Min B, Kim MK, Zhang JW, et al: Identification of RUNX3 as a component of the MST/Hpo signaling pathway. J Cell Physiol. 227:839–849. 2012. View Article : Google Scholar : PubMed/NCBI
20	Yoshihama Y, Izumisawa Y, Akimoto K, et al: High expression of KIBRA in low atypical protein kinase C-expressing gastric cancer correlates with lymphatic invasion and poor prognosis. Cancer Sci. 104:259–265. 2013. View Article : Google Scholar : PubMed/NCBI
21	Song M, Cheong JH and Kim H, Noh SH and Kim H: Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res. 32:3827–3834. 2012.PubMed/NCBI
22	Lam-Himlin DM, Daniels JA, Gayyed MF, et al: The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer. 37:103–109. 2006.PubMed/NCBI
23	Seymour JD, Calle EE, Flagg EW, Coates RJ, Ford ES and Thun MJ; American Cancer Society. Diet Quality Index as a predictor of short-term mortality in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Am J Epidemiol. 157:980–988. 2003. View Article : Google Scholar : PubMed/NCBI
24	Gao N, Cheng S, Budhraja A, et al: 3,3′-Diindolylmethane exhibits antileukemic activity in vitro and in vivo through a Akt-dependent process. PloS One. 7:e317832012.
25	Grose KR and Bjeldanes LF: Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol. 5:188–193. 1992. View Article : Google Scholar : PubMed/NCBI
26	Keck AS and Finley JW: Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr Cancer Ther. 3:5–12. 2004. View Article : Google Scholar : PubMed/NCBI
27	Banerjee S, Wang Z, Kong D and Sarkar FH: 3,3′-Diindolyl-methane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 69:5592–5600. 2009.
28	Kim SJ, Lee JS and Kim SM: 3,3′-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest. Oncol Rep. 27:1669–1673. 2012.
29	Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA and Sarkar FH: Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther. 7:1708–1719. 2008.PubMed/NCBI
30	Chinnakannu K, Chen D, Li Y, et al: Cell cycle-dependent effects of 3,3′-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol. 219:94–99. 2009.
31	Bhuiyan MM, Li Y, Banerjee S, et al: Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res. 66:10064–10072. 2006.
32	Li Y, Chinni SR and Sarkar FH: Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci. 10:236–243. 2005. View Article : Google Scholar : PubMed/NCBI
33	Nachshon-Kedmi M, Fares FA and Yannai S: Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. Prostate. 61:153–160. 2004.
34	Rahman KW and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res. 65:364–371. 2005.
35	Abdelrahim M, Newman K, Vanderlaag K, Samudio I and Safe S: 3,3′-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis. 27:717–728. 2006.
36	Carter TH, Liu K, Ralph W Jr, et al: Diindolylmethane alters gene expression in human keratinocytes in vitro. J Nutr. 132:3314–3324. 2002.PubMed/NCBI
37	Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM and Sarkar FH: Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3′ diindolylmethane (DIM). Pharm Res. 25:2117–2124. 2008.PubMed/NCBI
38	Kim SJ, Chung MJ, Kim JS, et al: Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. Int J Oncol. 39:1587–1591. 2011.PubMed/NCBI
39	Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 25:315–319. 2000. View Article : Google Scholar : PubMed/NCBI
40	Dammann R, Schagdarsurengin U, Seidel C, et al: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 20:645–663. 2005.PubMed/NCBI
41	Guo C, Zhang X and Pfeifer GP: The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 286:6253–6261. 2011. View Article : Google Scholar : PubMed/NCBI
42	Chen Y, Xu J, Jhala N, et al: Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3′-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol. 169:1833–1842. 2006.PubMed/NCBI
43	Saucedo LJ and Edgar BA: Filling out the Hippo pathway. Nat Rev Mol Cell Biol. 8:613–621. 2007. View Article : Google Scholar : PubMed/NCBI
44	Burbee DG, Forgacs E, Zöchbauer-Müller S, et al: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
45	Agathanggelou A, Cooper WN and Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 65:3497–3508. 2005. View Article : Google Scholar : PubMed/NCBI
46	Tommasi S, Dammann R, Zhang Z, et al: Tumor susceptibility of Rassf1a knockout mice. Cancer Res. 65:92–98. 2005.PubMed/NCBI
47	Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D and Hemmings BA: NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. Curr Biol. 18:1889–1895. 2008. View Article : Google Scholar : PubMed/NCBI
48	Guo C, Tommasi S, Liu L, Yee JK, Dammann R and Pfeifer GP: RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol. 17:700–705. 2007. View Article : Google Scholar : PubMed/NCBI
49	Matallanas D, Romano D, Yee K, et al: RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell. 27:962–975. 2007. View Article : Google Scholar : PubMed/NCBI